» Articles » PMID: 17520742

Hepatic Encephalopathy As a Predictor of Survival in Patients with End-stage Liver Disease

Overview
Journal Liver Transpl
Date 2007 May 24
PMID 17520742
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatic encephalopathy (HE) is an important component of hepatic decompensation, which reduces survival in patients with cirrhosis. The Model for End-Stage Liver Disease (MELD) score has been used to predict survival of patients with cirrhosis. The aims of this study were to determine whether HE is a predictor of survival of patients with cirrhosis and to examine the degree to which HE may add to the survival prediction of MELD. Patients with end-stage liver disease whose data were included in 2 databases were included in the analysis: 223 patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) insertion, and 271 patients hospitalized with hepatic decompensation. In univariate analysis, HE grade 3 or higher was associated with a 3.7-fold (95% confidence interval, 1.9-7.3, P<0.01) increase in the risk of death in the TIPS patients and HE grade 2 or higher was associated 3.9-fold increase (95% confidence interval [95% CI], 2.6-5.7, P<0.01) in hospitalized patients. As expected, MELD and Child-Turcotte-Pugh scores (with and without HE included) were also markedly associated with survival. When HE (grade 2 or higher) and MELD were considered together, HE remained strongly statistically significant in the hospitalized patients (hazard ratio=2.6, 95% CI, 1.7-3.8, P<0.01). The effect became smaller in the TIPS patients (hazard ratio=1.1; 95% CI, 0.7-1.6, P=0.76). In conclusion, this retrospective study demonstrates that HE is an important event in the natural history of cirrhosis that affects subsequent survival of patients. HE may provide additional prognostic information independent of MELD, which warrants prospective validation.

Citing Articles

TIPS and hepatic encephalopathy in patients with cirrhosis.

Bozon-Riviere P, Rudler M, Weiss N, Thabut D Metab Brain Dis. 2025; 40(2):117.

PMID: 39903376 DOI: 10.1007/s11011-025-01541-w.


Comparisons of efficacy and safety of 400 or 800 ml bacterial count fecal microbiota transplantation in the treatment of recurrent hepatic encephalopathy: a multicenter prospective randomized controlled trial in China.

Zou P, Bi Y, Tong Z, Wu T, Li Q, Wang K Trials. 2024; 25(1):799.

PMID: 39605077 PMC: 11600821. DOI: 10.1186/s13063-024-08578-9.


Prognosis of Cirrhotic Patients After Osteoporotic Femoral Neck Fracture.

Muallem A, Kandel L, Ackerman Z J Clin Med. 2024; 13(22).

PMID: 39597844 PMC: 11595005. DOI: 10.3390/jcm13226701.


Liver Stiffness Evaluation in Chronic Hepatitis C Patients with Cirrhosis before and after Direct-Acting Antivirals.

Stasi C, Brillanti S Microorganisms. 2024; 12(7).

PMID: 39065186 PMC: 11279336. DOI: 10.3390/microorganisms12071418.


Outcome Predictors of Acute-on-Chronic Liver Failure: A Narrative Review.

Batra N, Gaidhane S, Kumar S, Acharya S Cureus. 2024; 16(6):e61655.

PMID: 38966452 PMC: 11223737. DOI: 10.7759/cureus.61655.